News
Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.
Sarepta Therapeutics stock sinks further Tuesday after halting shipment of bestselling drug Elevidys
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
In May, Sarepta’s stock dropped further after it lowered its 2025 revenue guidance from $2.9 billion - $3.1 billion to $2.3 billion - $2.6 billion. This was attributed to ELEVIDYS.
Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $102.54, accompanied by a high estimate of $202.00 and a low estimate of $40.00. A ...
The Stock Declines as the Truth is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure.
7d
Zacks Investment Research on MSNSRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation — Contact BFA Law (NASDAQ:SRPT) Provided by GlobeNewswire Jun 24, 2025, 12:18:00 PM ...
StockStory.org on MSN9d
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.
A second Duchenne patient being treated with Sarepta's gene therapy has died, sending the biotech's stock plummeting. Thursday, July 31, 2025 Biotech's Future - Innovation, AI and our Competitive Edge ...
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results